Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice

Zhao, Yarui; Dong, Jianyu; Li, Yue; Wu, Minchen

doi:10.1016/j.lfs.2012.04.003

Cited by 24 publications

(12 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SMases may hydrolyze LDL-sphingomyelin in the arterial wall increasing LDL-ceramide and aggregation of lipoproteins leading to initiation and progression of atherosclerosis 49 . Over expression of SMS2 in mice exaggerates atherosclerotic inflammation 50 , whereas inhibition of sphingolipid synthesis by myriocin reduces atherosclerosis 51 . Further, LDL receptor knockout mice transplanted with bone marrow cells derived from Sms2 − / − mice show decreased atherosclerotic lesions 52 .…”

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Iqbal

Walsh

Hammad

et al. 2017

Trends in Endocrinology & Metabolism

196

160

View full text Add to dashboard Cite

Sphingolipids are structurally and functionally diverse molecules with significant physiologic functions and are found associated with cellular membranes and plasma lipoproteins. The cellular and plasma concentrations of sphingolipids are altered in several metabolic disorders and may serve as prognostic and diagnostic markers. Here, we discuss different sphingolipid transport mechanisms and highlight how changes in cellular and plasma sphingolipids levels contribute to cardiovascular disease, obesity, diabetes, insulin resistance and nonalcoholic fatty liver disease. Understanding mechanisms involved in intracellular transport, secretion and extracellular transport may provide novel information that might be amenable to therapeutic targeting in the treatment of various metabolic disorders.

show abstract

Section: Cardiovascular Diseasesmentioning

confidence: 99%

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Iqbal

Walsh

Hammad

et al. 2017

Trends in Endocrinology & Metabolism

196

160

View full text Add to dashboard Cite

show abstract

“…Consistently, LDL from SMS2 transgenic mice exhibit proatherogenic properties with increased in vitro aggregation upon SMase treatment [ 35 ]. Also, SMS2 overexpression in mice with adenovirus exaggerated atherosclerotic inflammation with elevations in cyclooxygenase-2 (COX-2) and matrix metalloproteinase-2 (MMP-2) in aorta [ 91 ]. Myriocin treatment decreased sphingomyelin and ceramide levels in plasma and consequently resulted in less atherosclerotic lesions in aorta from HFD-fed Apo-E deficient mice [ 87 , 92 , 93 ].…”

Section: Sphingolipids In Hfd-induced Pathobiologymentioning

confidence: 99%

Sphingolipids in High Fat Diet and Obesity‐Related Diseases

Choi

Snider

2015

Mediators of Inflammation

114

View full text Add to dashboard Cite

Nutrient oversupply associated with a high fat diet (HFD) significantly alters cellular metabolism, and specifically including sphingolipid metabolism. Sphingolipids are emerging as bioactive lipids that play key roles in regulating functions, in addition to their traditional roles as membrane structure. HFD enhances de novo sphingolipid synthesis and turnover of sphingolipids via the salvage pathway, resulting in the generation of ceramide, and more specifically long chain ceramide species. Additionally, HFD elevates sphingomyelin and sphingosine-1 phosphate (S1P) levels in several tissues including liver, skeletal muscle, adipose tissue, and cardiovascular tissues. HFD-stimulated sphingolipid generation contributes to systemic insulin resistance, dysregulated lipid accumulation, and cytokine expression and secretion from skeletal muscle and adipose tissues, exacerbating obesity-related conditions. Furthermore, altered sphingolipid levels, particularly ceramide and sphingomyelin, are involved in obesity-induced endothelial dysfunction and atherosclerosis. In this review, HFD-mediated sphingolipid metabolism and its impact on HFD-induced biology and pathobiology will be discussed.

show abstract

“…Inhibition of SMS in EC was reported to attenuate lipopolysaccaride (LPS)-induced lung injury in animals through enhancement of the EC barrier by reducing loss of SM from lipid rafts in the cell membrane 27 . Elevated plasma SM levels are a prognostic marker in acute coronary syndrome 28 , and overexpression of SMS is suggested to be related to EC dysfunction, a decrease of CD34/KDR-positive endothelial progenitor cells, and development of atherosclerosis in ApoE knock-out mice 29 . Thus, plasmalogens and SM play an important role in EC function and their plasma levels reflect various disease states.…”

Section: Introductionmentioning

confidence: 99%

Changes of plasmalogen phospholipid levels during differentiation of induced pluripotent stem cells 409B2 to endothelial phenotype cells

Nakamura

Shimizu

Horibata

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Endothelial cells (EC) are involved in regulating several aspects of lipid metabolism, with recent research revealing the clinicopathological significance of interactions between EC and lipids. Induced pluripotent stem cells (iPSC) have various possible medical uses, so understanding the metabolism of these cells is important. In this study, endothelial phenotype cells generated from human iPSC formed cell networks in co-culture with fibroblasts. Changes of plasmalogen lipids and sphingomyelins in endothelial phenotype cells generated from human iPSC were investigated by reverse-phase ultra-high-pressure liquid chromatography mass spectrometry (UHPLC-MS/MS) analysis. The levels of plasmalogen phosphatidylethanolamines (38:5) and (38:4) increased during differentiation of EC, while sphingomyelin levels decreased transiently. These changes of plasmalogen lipids and sphingomyelins may have physiological significance for EC and could be used as markers of differentiation.

show abstract

Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice

Cited by 24 publications

References 43 publications

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Sphingolipids and Lipoproteins in Health and Metabolic Disorders

Sphingolipids in High Fat Diet and Obesity‐Related Diseases

Changes of plasmalogen phospholipid levels during differentiation of induced pluripotent stem cells 409B2 to endothelial phenotype cells

Contact Info

Product

Resources

About